CDM Insights
JSON twin: https://www.healthaidb.com/software/cdm-insights.json
Company Name
Oxford Brain Diagnostics
Product URL
https://www.oxfordbraindiagnostics.com/products/
Company URL
https://www.oxfordbraindiagnostics.com/
Categories
Summary
CDM Insights is an FDA-cleared MRI software by Oxford Brain Diagnostics that provides detailed assessments of brain microstructure to aid in early detection of neurodegenerative diseases like Alzheimer's.
Description
CDM Insights utilizes Cortical Disarray Measurement (CDM®) technology to analyze MRI scans, offering insights into cortical microstructure and thickness, as well as macrostructural measures. It processes data from both 1.5T and 3T MRI scanners, delivering outputs as images and numerical values, typically presented as percentiles of a normative population distribution. The software is cloud-native, non-invasive, and monitors brain changes across multiple stages of adult life. It is intended for use by neurologists, radiologists, and other trained healthcare practitioners familiar with MRI post-processing. CDM Insights is not intended to be used in isolation for diagnosis or treatment decisions; the physician retains the ultimate responsibility for making any final diagnosis and treatment decisions.
Api Available
unknown
Certifications
- FDA 510(k) clearance
- ISO 13485
- ISO 27001
Company Founding
2018
Company Offices
Compliance
- HIPAA
- GDPR
- ISO 13485
- ISO 27001
Customers
Data Residency
US and EU regions
Data Standards
Deployment Model
Features
- Non-invasive analysis of brain microstructure from standard MRI scans
- Quantitative assessment of cortical thickness and regional volumes
- Measurement of white matter hyper-/hypointensities
- Longitudinal tracking of brain changes across multiple time points
- Integration with hospital PACS systems for secure cloud processing
- Rapid report generation within 12 hours of scan upload
- FDA 510(k) clearance for clinical use in neurodegenerative conditions
- ISO 13485 and ISO 27001 certifications for quality and security
Id
SW0119
Integration Partners
Integrations
Languages Supported
Last Updated
2025-10-11
License
commercial
Market Segment
Optional Modules
- Disease stage classification
- Prediction of patient disease progression
- Dropout rate and cost reduction in clinical trials
Os Platforms
Pricing Details
contact vendor
Pricing Model
subscription
Privacy Features
- BAA available
- Consent management
- Anonymization
- Data minimization
Product Code
SW0119
Product Name
CDM Insights
Ratings
- 5/5 (2 reviews) - G2
- 5/5 (5 reviews) - G2
Regions Available
Related Urls
Release Year
2019
Security Features
- Encryption
- RBAC
- Audit logs
- 2FA
Specialties
Support Channels
- email
- phone
- chat
- ticketing
- community
- 24x7
System Requirements
Target Users
- neurologists
- radiologists
- neuroimaging specialists
- healthcare practitioners
Training Options
- documentation
- webinars
- live_online
- onsite
- certification
Type
product
User Reviews
- Mainly I am very pleased with his way of taking decisions, a true and authentic way to solve a problem.
- delighted with tremendous company, I personally like that company because it provides me with a series of tools to obtain solutions based on saving time and thus increase collaboration to provide a better and effective decision making.
Version
1.0
Alternatives
See related products
Canonical JSON
{
"product_name": "CDM Insights",
"company_name": "Oxford Brain Diagnostics",
"product_url": "https://www.oxfordbraindiagnostics.com/products/",
"company_url": "https://www.oxfordbraindiagnostics.com/",
"related_urls": [
"https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices"
],
"product_code": "SW0119",
"summary": "CDM Insights is an FDA-cleared MRI software by Oxford Brain Diagnostics that provides detailed assessments of brain microstructure to aid in early detection of neurodegenerative diseases like Alzheimer's.",
"description": "CDM Insights utilizes Cortical Disarray Measurement (CDM®) technology to analyze MRI scans, offering insights into cortical microstructure and thickness, as well as macrostructural measures. It processes data from both 1.5T and 3T MRI scanners, delivering outputs as images and numerical values, typically presented as percentiles of a normative population distribution. The software is cloud-native, non-invasive, and monitors brain changes across multiple stages of adult life. It is intended for use by neurologists, radiologists, and other trained healthcare practitioners familiar with MRI post-processing. CDM Insights is not intended to be used in isolation for diagnosis or treatment decisions; the physician retains the ultimate responsibility for making any final diagnosis and treatment decisions.",
"categories": [
"diagnostic Support",
"clinical Care",
"imaging Software",
"healthcare Software Solutions",
"Diagnostic",
"Clinical",
"Neuroimaging",
"Medical Imaging",
"Healthcare Software"
],
"market_segment": [
"enterprise",
"smb"
],
"target_users": [
"neurologists",
"radiologists",
"neuroimaging specialists",
"healthcare practitioners"
],
"specialties": [
"Neurology",
"Radiology",
"Neurodegenerative Diseases",
"Alzheimer's Disease",
"Neuroimaging"
],
"regions_available": [
"United States",
"United Kingdom",
"Europe",
"Canada",
"Australia"
],
"languages_supported": [
"English"
],
"pricing_model": "subscription",
"pricing_details": "contact vendor",
"license": "commercial",
"company_offices": [
"United Kingdom",
"United States",
"Germany",
"France",
"Canada"
],
"company_founding": "2018",
"deployment_model": [
"SaaS"
],
"os_platforms": [
"Web"
],
"features": [
"Non-invasive analysis of brain microstructure from standard MRI scans",
"Quantitative assessment of cortical thickness and regional volumes",
"Measurement of white matter hyper-/hypointensities",
"Longitudinal tracking of brain changes across multiple time points",
"Integration with hospital PACS systems for secure cloud processing",
"Rapid report generation within 12 hours of scan upload",
"FDA 510(k) clearance for clinical use in neurodegenerative conditions",
"ISO 13485 and ISO 27001 certifications for quality and security"
],
"optional_modules": [
"Disease stage classification",
"Prediction of patient disease progression",
"Dropout rate and cost reduction in clinical trials"
],
"integrations": [
"Hospital PACS systems"
],
"data_standards": [
"DICOM",
"HL7",
"FHIR"
],
"api_available": "unknown",
"system_requirements": "",
"compliance": [
"HIPAA",
"GDPR",
"ISO 13485",
"ISO 27001"
],
"certifications": [
"FDA 510(k) clearance",
"ISO 13485",
"ISO 27001"
],
"security_features": [
"Encryption",
"RBAC",
"Audit logs",
"2FA"
],
"privacy_features": [
"BAA available",
"Consent management",
"Anonymization",
"Data minimization"
],
"data_residency": "US and EU regions",
"customers": [
"Oxford Brain Diagnostics"
],
"user_reviews": [
"Mainly I am very pleased with his way of taking decisions, a true and authentic way to solve a problem.",
"delighted with tremendous company, I personally like that company because it provides me with a series of tools to obtain solutions based on saving time and thus increase collaboration to provide a better and effective decision making."
],
"ratings": [
"5/5 (2 reviews) - G2",
"5/5 (5 reviews) - G2"
],
"support_channels": [
"email",
"phone",
"chat",
"ticketing",
"community",
"24x7"
],
"training_options": [
"documentation",
"webinars",
"live_online",
"onsite",
"certification"
],
"release_year": "2019",
"integration_partners": [
"D-Sight"
],
"id": "SW0119",
"slug": "cdm-insights",
"type": "product",
"version": "1.0",
"last_updated": "2025-10-11",
"links_json": {
"self": "https://www.healthaidb.com/software/cdm-insights.json"
}
}